BFM
PGNX

Boothbay Fund Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Boothbay Fund Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-45,300
Closed -$428K – 920
2017
Q1 		$428K Buy
+45,300
New +$452K 0.08% 290

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.9B AUM 39.77% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Boothbay Fund Management's PGNX Position: Q2 2020 in Review

Boothbay Fund Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 24,144 shares — an estimated $92K sold.

Boothbay Fund Management first reported a position in PGNX in Q1 2016 and held it in 5 quarters. The position peaked at $697K in Q3 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Boothbay Fund Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 24,144 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $92K.
  • Boothbay Fund Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2016 and held it in 5 quarters.
  • Boothbay Fund Management's Progenics Pharmaceuticals Inc position peaked at $697K in Q3 2019.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Boothbay Fund Management's 13F filing for Q2 2020, filed 14 Aug 2020.